CCM
ESPR

CAAS Capital Management’s Esperion Therapeutics ESPR Stock Holding History

CAAS Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$2.12M – 1004
2021
Q2 		$2.12M Hold
100,000
– – 0.04% 388
2021
Q1 		$2.81M Buy
+100,000
New +$2.95M 0.03% 509

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAAS Capital Management's ESPR Position: Q3 2021 in Review

CAAS Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 29,000 shares — an estimated $613K sold.

CAAS Capital Management first reported a position in ESPR in Q1 2021 and held it in 2 quarters. The position peaked at $813K in Q1 2021. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • CAAS Capital Management reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 29,000 Esperion Therapeutics shares in Q3 2021, an estimated $613K.
  • CAAS Capital Management first reported a position in Esperion Therapeutics in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Esperion Therapeutics position peaked at $813K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.